Orion and Gedeon Richter announce cognitive disorder alliance

Orion has formed a new alliance with fellow pharmaceutical company Gedeon Richter, focusing on the development of new treatments for cognitive disorders.

Under the terms of the agreement, the organisations will jointly select and bring forward three discovery phase candidates for development, sharing all related expenses on an equal basis.

Territory marketing rights to these products will be determined at a later date, with the comprehensive and long-term collaboration deal set to offer a number of advantages.

Staff from Orion and Gedeon Richter have expressed confidence that this partnership will leverage the strengths and expertise of both companies in a way that will be mutually beneficial.

Dr Reijo Salonen, senior vice-president for research and development at Orion, said: "This collaboration increases probability to succeed in this this challenging therapeutic area. Colleagues from both companies are looking forward to working together in the future."

Orion is currently working on a number of cognitive disorder therapies, including ODM-101, a levodopa-based treatment for Parkinson's disease that successfully completed a phase II proof of concept trial last year.